Digitalici e insufficienza cardiaca.

The current guidelines of the European Society of Cardiology recommend the use of cardiac glycosides/digitalis in patients with heart failure and sinus rhythm only if the LVEF is ≤40% and if heart failure symptoms persist despite therapy with Betablockers, ACE inhibitors (or angiotensin receptor-neprilysin inhibitors), and mineralocorticoid receptor antagonists, in order to reduce the risk of further hospitalizations. Therapy with cardiac glycosides is not recommended in heart failure with an LVEF >40% and sinus rhythm. In patients with atrial fibrillation, therapy with cardiac glycosides may be used primarily for rate control in heart failure with an LVEF >40%, and in those with an LVEF ≤40